What is Ascendis Pharma AS's share price today?
Ascendis Pharma AS (ASND) share price today is $255.00 as of November 6, 2026 at 10:11 PM IST. The stock touched a day high of $256.87 and a day low of $251.58.What exchange does Ascendis Pharma AS stock trade on, and under what ticker symbol?
Ascendis Pharma AS stock trades on NASDAQ under the ticker symbol ASND.What is Ascendis Pharma AS's market capitalization?
Ascendis Pharma AS's market capitalization is $16.97B as of November 6, 2026 at 10:11 PM IST.What is Ascendis Pharma AS's price-to-earnings (P/E) ratio?
Ascendis Pharma AS's price-to-earnings (P/E) ratio is 19.76 as of November 6, 2026.What is Ascendis Pharma AS's price-to-book (P/B) ratio?
Ascendis Pharma AS's price-to-book (P/B) ratio is 10.27 as of November 6, 2026.Can Indian investors buy Ascendis Pharma AS shares?
Yes, You can buy Ascendis Pharma AS shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Ascendis Pharma AS shares from India?
Indian investors can buy Ascendis Pharma AS shares in three steps: 1. Search Ascendis Pharma AS on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Ascendis Pharma AS shares for Indian investors?
Since Ascendis Pharma AS trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Ascendis Pharma AS shares via Tickertape?
Indian investors can start investing in Ascendis Pharma AS (ASND) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0392 shares at the current price of $255.00.
$
₹
$2550.61% (+1.55)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
19.76
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
10.27
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$13.05
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
70.85%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 22 analysts reports
Buy21 analysts
Hold1 analyst
Sell0 analyst
Price Upside
+18.53%
Earnings Growth
+348.22%
Rev. Growth
+97.75%
Company Profile
Company Profile
ABBV
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$257.93Baseline
Analyst Target - 1 year
Target$305.73+18.53%
All values in $
2026
Current$257.93Baseline
Analyst Target - 1 year
Target$305.73+18.53%
All values in $
Revenue Forecast
Revenue Forecast
Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 97.75% growth, versus a trailing 3-year CAGR of 138.21%.
2025
Current$691.71Baseline
Forecast for Dec 2026
High$1,509.3+118.2%
Average$1,367.85+97.75%
Low$1,328.05+92%
All values in $ Million
2025
Current$691.71Baseline
Forecast for Dec 2026
High$1,509.3+118.2%
Average$1,367.85+97.75%
Low$1,328.05+92%
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-4.06Baseline
Forecast for Dec 2026
High$15.62+484.68%
Average$10.08+348.22%
Low$3.61+188.92%
All values in $
2025
Current$-4.06Baseline
Forecast for Dec 2026
High$15.62+484.68%
Average$10.08+348.22%
Low$3.61+188.92%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 95.89 | 35.99 | 57.83 | 173.91 | 100.95 | 158.04 | 213.63 | 245.17 | 250.65 | 344.90 |
Gross Profit | 88.32 | 24.53 | 46.63 | 159.89 | 83.43 | 126.59 | 191.28 | 217.98 | 229.03 | 312.60 |
| Net Income | -131.03 | -109.38 | -99.19 | -38.46 | -94.62 | -38.85 | -60.98 | -33.24 | 639.68 | 210.39 |
| Net Profit Margin | -136.64% | -303.85% | -171.52% | -22.11% | -93.73% | -24.58% | -28.54% | -13.56% | 255.20% | 61.00% |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Ascendis Pharma AS | 19.76 | 10.27 | - |
| AbbVie Inc | 50.65 | 50.45 | 0.58 |
| Amgen Inc | 27.73 | 21.33 | 2.75 |
Price Comparison
Price Comparison
Compare ASND with any stock or ETFCompare ASND with any stock or ETF
Comparing from
ASND
ABBV
AMGN
The 12-month consensus target implies 18.53% growth, versus a trailing 3-year CAGR of 39.80%.